Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Astrazeneca Ab Drug Patent Portfolio

Astrazeneca Ab owns 13 orange book drugs protected by 100 US patents with Onglyza having the least patent protection, holding only 3 patents. And Bydureon Pen with maximum patent protection, holding 60 patents. Given below is the list of Astrazeneca Ab's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10973836 Methods of treating heart failure with reduced ejection fraction 09 Sep, 2040
Active
US11903955 Methods of treating heart failure with reduced ejection fraction 09 Sep, 2040
Active
US10973836 Methods of treating heart failure with reduced ejection fraction 09 Mar, 2040
Active
US11903955 Methods of treating heart failure with reduced ejection fraction 09 Mar, 2040
Active
US11826376 Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same 18 Jan, 2040
Active
US11826376 Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same 18 Jul, 2039
Active
US11331442 Drug delivery systems and related methods 05 Oct, 2038
Active
US11833292 Drug delivery systems and related methods 05 Oct, 2038
Active
US10683499 Compositions and methods for modulating TTR expression 25 Aug, 2034
Active
US9127276 Conjugated antisense compounds and their use 01 May, 2034
Active
US9181549 Conjugated antisense compounds and their use 01 May, 2034
Active
US9616028 Bilayer tablet formulations 12 May, 2031
Active
US8895033 Sustained release formulations using non-aqueous carriers 04 Apr, 2031
Active
US8815258 Compositions, methods and systems for respiratory delivery of two or more active agents 17 Mar, 2031
Active
US8685934 Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof 26 Nov, 2030
Active
US9616028 Bilayer tablet formulations 12 Nov, 2030
Active
US8895033 Sustained release formulations using non-aqueous carriers 04 Oct, 2030
Active
US8721615 Ampoule comprising an ampoule holder 18 Jul, 2030
Active
US8998876 Ampoule comprising an ampoule holder 07 Jul, 2030
Active
US7919598 Crystal structures of SGLT2 inhibitors and processes for preparing same 16 Jun, 2030
Active
US10716753 Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems 28 May, 2030
Active
US8324266 Compositions, methods and systems for respiratory delivery of two or more active agents 28 May, 2030
Active
US8703806 Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents 28 May, 2030
Active
US8808713 Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems 28 May, 2030
Active
US9415009 Compositions, methods and systems for respiratory delivery of two or more active agents 28 May, 2030
Active
US9463161 Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems 28 May, 2030
Active
US8685934 Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof 26 May, 2030
Active
US8721615 Ampoule comprising an ampoule holder 18 Jan, 2030
Active
US8998876 Ampoule comprising an ampoule holder 07 Jan, 2030
Active
US7919598 Crystal structures of SGLT2 inhibitors and processes for preparing same 16 Dec, 2029
Active
US8690837 Mixing device for a two-chamber ampoule 19 Nov, 2029
Active
US8827963 Administering device with holding mechanism 04 Aug, 2029
Active
US8690837 Mixing device for a two-chamber ampoule 19 May, 2029
Active
US7851502 Pharmaceutical formulations containing an SGLT2 inhibitor 19 Feb, 2029
Active
US8827963 Administering device with holding mechanism 04 Feb, 2029
Active
US7951400 Coated tablet formulation and method 30 Nov, 2028
Active
US8439864 Device for administering fluid from a multi-chamber ampoule in incremental steps 25 Sep, 2028
Active
US9320853 Method for administering a fluid active substance from a multi-chamber ampoule 25 Sep, 2028
Active
US8361972 Pharmaceutical formulations containing an SGLT2 inhibitor 21 Sep, 2028
Active
US8221786 Pharmaceutical formulations containing an SGLT2 inhibitor 21 Sep, 2028
Active
US8716251 Pharmaceutical formulations containing an SGLT2 inhibitor 21 Sep, 2028
Active
US7851502 Pharmaceutical formulations containing an SGLT2 inhibitor 19 Aug, 2028
Active
US8216180 Administering apparatus with functional drive element 12 Jul, 2028
Active
US8758292 Administering apparatus with functional drive element 12 May, 2028
Active
US8439864 Device for administering fluid from a multi-chamber ampoule in incremental steps 25 Mar, 2028
Active
US9320853 Method for administering a fluid active substance from a multi-chamber ampoule 25 Mar, 2028
Active
US8221786 Pharmaceutical formulations containing an SGLT2 inhibitor 21 Mar, 2028
Active
US8361972 Pharmaceutical formulations containing an SGLT2 inhibitor 21 Mar, 2028
Active
US8716251 Pharmaceutical formulations containing an SGLT2 inhibitor 21 Mar, 2028
Active
US8216180 Administering apparatus with functional drive element 12 Jan, 2028
Active
US8501698 Crystal structures of SGLT2 inhibitors and processes for preparing same 20 Dec, 2027
Active
US8758292 Administering apparatus with functional drive element 12 Nov, 2027
Active
US8501698 Crystal structures of SGLT2 inhibitors and processes for preparing same 20 Jun, 2027
Active
US8329648 Methods for treating diabetes and reducing body weight 18 Feb, 2027
Active
US8906851 Method for treating diabetes 18 Feb, 2027
Active
US9884092 Methods for treating diabetes and reducing body weight 18 Feb, 2027
Active
US8329648 Methods for treating diabetes and reducing body weight 18 Aug, 2026
Active
US8906851 Method for treating diabetes 18 Aug, 2026
Active
US9884092 Methods for treating diabetes and reducing body weight 18 Aug, 2026
Active
US6515117 C-aryl glucoside SGLT2 inhibitors and method 04 Apr, 2026
Active
US7456254 Polymer-based sustained release device 30 Dec, 2025
Active
US7612176 Polymer-based sustained release device 13 Oct, 2025
Active
US8431685 Polymer-based sustained release device 13 Oct, 2025
Active
US8461105 Polymer-based sustained release device 13 Oct, 2025
Active
US6515117 C-aryl glucoside SGLT2 inhibitors and method 04 Oct, 2025
Active
US8628799 Coated tablet formulation and method 13 Jul, 2025
Active
US9339472 Coated tablet formulation and method 13 Jul, 2025
Active
US7456254 Polymer-based sustained release device 30 Jun, 2025
Active
US7612176 Polymer-based sustained release device 13 Apr, 2025
Active
US8431685 Polymer-based sustained release device 13 Apr, 2025
Active
US8461105 Polymer-based sustained release device 13 Apr, 2025
Active
US8101743 Modulation of transthyretin expression 01 Apr, 2025
Active
US7563871 Polymer-based sustained release device 15 Oct, 2024 Expired
US9238076 Polymer-based sustained release device 15 Oct, 2024 Expired
US7563871 Polymer-based sustained release device 15 Apr, 2024 Expired
US9238076 Polymer-based sustained release device 15 Apr, 2024 Expired
USRE44186 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method 31 Jul, 2023 Expired
US6824822 Residual solvent extraction method and microparticles produced thereby 09 Apr, 2023 Expired
US6824822 Residual solvent extraction method and microparticles produced thereby 09 Oct, 2022 Expired
US7223440 Residual solvent extraction method and microparticles produced thereby 03 Mar, 2022 Expired
US7223440 Residual solvent extraction method and microparticles produced thereby 31 Aug, 2021 Expired
US6395767 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method 16 Feb, 2021 Expired
US6414126 C-aryl glucoside SGLT2 inhibitors and method 04 Oct, 2020 Expired
US6936590 C-aryl glucoside SGLT2 inhibitors and method 04 Oct, 2020 Expired
US9198925 Pharmaceutical formulations containing an SGLT2 inhibitor 04 Oct, 2020 Expired
US6479065 Process for the preparation of polymer-based sustained release compositions 10 Aug, 2020 Expired
US6495164 Preparation of injectable suspensions having improved injectability 25 May, 2020 Expired
US6667061 Preparation of injectable suspensions having improved injectability 25 May, 2020 Expired
US6872700 Methods for glucagon suppression 14 Jan, 2020 Expired
US6902744 Exendin agonist formulations and methods of administration thereof 14 Jan, 2020 Expired
US5686411 Amylin agonist peptides and uses therefor 16 Mar, 2019 Expired
US6956026 Use of exendins for the reduction of food intake 07 Jan, 2018 Expired
US7741269 Exendins and exendin agonists for weight reduction and obesity 07 Jan, 2018 Expired
US7297761 Pharmaceutical compositions containing exendins 15 Oct, 2017 Expired
US7521423 Exendin pharmaceutical compositions 15 Oct, 2017 Expired
US6114304 Methods for regulating gastrointestinal motility 05 Sep, 2017 Expired
US6858576 Methods for regulating gastrointestinal motility 06 Jan, 2017 Expired
US5424286 Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same 01 Dec, 2016 Expired
US5814600 Method and composition for treatment of insulin requiring mammals 29 Sep, 2015 Expired
US6608029 Methods for regulating gastrointestinal motility 07 Sep, 2013 Expired


Given below is the list of recent legal activities going on the following drug patents of Astrazeneca Ab.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 17 Jul, 2024 US8361972
Payment of Maintenance Fee, 12th Year, Large Entity 17 Jul, 2024 US8361972
Payment of Maintenance Fee, 12th Year, Large Entity 17 Jul, 2024 US8361972
Payment of Maintenance Fee, 12th Year, Large Entity 17 Jul, 2024 US8361972
Payment of Maintenance Fee, 12th Year, Large Entity 29 May, 2024 US8329648
Payment of Maintenance Fee, 12th Year, Large Entity 29 May, 2024 US8329648
Payment of Maintenance Fee, 12th Year, Large Entity 29 May, 2024 US8329648
Payment of Maintenance Fee, 12th Year, Large Entity 29 May, 2024 US8329648
Payment of Maintenance Fee, 12th Year, Large Entity 22 May, 2024 US8324266
Patent eCofC Notification 09 Apr, 2024 US11903955
Mail Patent eCofC Notification 09 Apr, 2024 US11903955
Recordation of Patent eCertificate of Correction 09 Apr, 2024 US11903955
Email Notification
Critical
09 Apr, 2024 US11903955
Payment of Maintenance Fee, 8th Year, Large Entity 27 Mar, 2024 US9463161
Mail Certificate of Correction Memo 13 Mar, 2024 US11903955


Astrazeneca Ab's Drug Patent Litigations

Astrazeneca Ab's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Dec 16, 2015, against patent number US7297761. The petitioner Sanofi-Aventis U.S. LLC, challenged the validity of this patent, with Amylin Pharmaceuticals, LLC as the respondent. Click below to track the latest information on how companies are challenging Astrazeneca Ab's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US6667061 May, 2016 FWD Entered
(28 Nov, 2017)
Alkermes Controlled Therapeutics, Inc. Luye Pharma Group Ltd.
US6667061 May, 2016 Terminated-Denied
(30 Nov, 2016)
Alkermes Controlled Therapeutics, Inc. Luye Pharma Group Ltd.
US7297761 December, 2015 Terminated-Denied
(28 Jun, 2016)
Amylin Pharmaceuticals, LLC Sanofi-Aventis U.S. LLC


Astrazeneca Ab Drug Patents' Oppositions Filed in EPO

Astrazeneca Ab drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Apr 30, 2015, by Lek Pharmaceuticals D.D.. This opposition was filed on patent number EP07784499A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP09812292A Jan, 2021 Instone, Terry/Read, Howard Graham/Appleyard Lees IP LLP Granted and Under Opposition
EP08732695A Dec, 2020 Kraus & Weisert Patentanwälte PartGmbB Granted and Under Opposition
EP08732695A Dec, 2020 Generics [UK] Limited Granted and Under Opposition
EP08732695A Dec, 2020 Stada-Arzneimittel Aktiengesellschaft Granted and Under Opposition
EP08732695A Dec, 2020 Gedeon Richter Plc. Granted and Under Opposition
EP08732695A Dec, 2020 Galenicum Health S.L.U. Granted and Under Opposition
EP08732695A Dec, 2020 Zentiva, k.s. Granted and Under Opposition
EP17203302A Aug, 2020 Generics (U.K.) Limited Granted and Under Opposition
EP10016112A Feb, 2020 Generics (UK) Ltd Granted and Under Opposition
EP10016112A Jan, 2020 Instone, Terry/Appleyard Lees IP LLP/Read, Howard Granted and Under Opposition
EP10782113A Apr, 2019 Hoefer & Partner Patentanwälte mbB Granted and Under Opposition
EP15181545A Sep, 2018 Generics (U.K.) Limited Granted and Under Opposition
EP08716685A Apr, 2017 SHL Group AB Opposition rejected
EP10179007A Mar, 2017 Galenicum Health S.L. Patent maintained as amended
EP05756474A Jan, 2017 Galenicum Health S.L. Patent maintained as amended
EP11180259A Nov, 2015 Teva Pharmaceutical Industries Ltd. Opposition rejected
EP11180259A Nov, 2015 PHARMATHEN S.A. Opposition rejected
EP06801867A Sep, 2015 Generics [UK] Ltd (trading as Mylan) Revoked
EP06801867A Sep, 2015 COOLEY LLP Revoked
EP06801867A Sep, 2015 Teva Pharmaceutical Industries Ltd. Revoked
EP06801867A Sep, 2015 PENTAFARMA, Sociedade Técnico-Medicinal, SA Revoked
EP06801867A Sep, 2015 Glaxo Group Limited Revoked
EP06801867A Aug, 2015 PHARMATHEN S.A. Revoked
EP07784499A Apr, 2015 LEK Pharmaceuticals d.d. Patent maintained as amended


Astrazeneca Ab's Family Patents

Astrazeneca Ab drugs have patent protection in a total of 53 countries. It's US patent count contributes only to 20.1% of its total global patent coverage. 7 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Astrazeneca Ab Drug List

Given below is the complete list of Astrazeneca Ab's drugs and the patents protecting them.


1. Breztri Aerosphere

Breztri Aerosphere is protected by 9 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11331442 Drug delivery systems and related methods 05 Oct, 2038
(13 years from now)
Active
US11833292 Drug delivery systems and related methods 05 Oct, 2038
(13 years from now)
Active
US8815258 Compositions, methods and systems for respiratory delivery of two or more active agents 17 Mar, 2031
(6 years from now)
Active
US10716753 Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems 28 May, 2030
(5 years from now)
Active
US8324266 Compositions, methods and systems for respiratory delivery of two or more active agents 28 May, 2030
(5 years from now)
Active
US8703806 Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents 28 May, 2030
(5 years from now)
Active
US8808713 Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems 28 May, 2030
(5 years from now)
Active
US9415009 Compositions, methods and systems for respiratory delivery of two or more active agents 28 May, 2030
(5 years from now)
Active
US9463161 Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems 28 May, 2030
(5 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Breztri Aerosphere's drug page


2. Bydureon

Bydureon is protected by 46 patents, out of which 19 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8685934 Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof 26 May, 2030
(5 years from now)
Active
US7919598 Crystal structures of SGLT2 inhibitors and processes for preparing same 16 Dec, 2029
(4 years from now)
Active
US8361972
(Pediatric)
Pharmaceutical formulations containing an SGLT2 inhibitor 21 Sep, 2028
(3 years from now)
Active
US7851502 Pharmaceutical formulations containing an SGLT2 inhibitor 19 Aug, 2028
(3 years from now)
Active
US8439864 Device for administering fluid from a multi-chamber ampoule in incremental steps 25 Mar, 2028
(3 years from now)
Active
US8221786 Pharmaceutical formulations containing an SGLT2 inhibitor 21 Mar, 2028
(3 years from now)
Active
US8361972 Pharmaceutical formulations containing an SGLT2 inhibitor 21 Mar, 2028
(3 years from now)
Active
US8716251 Pharmaceutical formulations containing an SGLT2 inhibitor 21 Mar, 2028
(3 years from now)
Active
US8216180 Administering apparatus with functional drive element 12 Jan, 2028
(3 years from now)
Active
US8501698
(Pediatric)
Crystal structures of SGLT2 inhibitors and processes for preparing same 20 Dec, 2027
(2 years from now)
Active
US8501698 Crystal structures of SGLT2 inhibitors and processes for preparing same 20 Jun, 2027
(2 years from now)
Active
US8329648
(Pediatric)
Methods for treating diabetes and reducing body weight 18 Feb, 2027
(2 years from now)
Active
US8906851
(Pediatric)
Method for treating diabetes 18 Feb, 2027
(2 years from now)
Active
US9884092
(Pediatric)
Methods for treating diabetes and reducing body weight 18 Feb, 2027
(2 years from now)
Active
US8329648 Methods for treating diabetes and reducing body weight 18 Aug, 2026
(1 year, 7 months from now)
Active
US8906851 Method for treating diabetes 18 Aug, 2026
(1 year, 7 months from now)
Active
US9884092 Methods for treating diabetes and reducing body weight 18 Aug, 2026
(1 year, 7 months from now)
Active
US6515117
(Pediatric)
C-aryl glucoside SGLT2 inhibitors and method 04 Apr, 2026
(1 year, 3 months from now)
Active
US7456254
(Pediatric)
Polymer-based sustained release device 30 Dec, 2025
(1 year, 8 days from now)
Active
US7612176
(Pediatric)
Polymer-based sustained release device 13 Oct, 2025
(9 months from now)
Active
US8431685
(Pediatric)
Polymer-based sustained release device 13 Oct, 2025
(9 months from now)
Active
US8461105
(Pediatric)
Polymer-based sustained release device 13 Oct, 2025
(9 months from now)
Active
US6515117 C-aryl glucoside SGLT2 inhibitors and method 04 Oct, 2025
(9 months from now)
Active
US7456254 Polymer-based sustained release device 30 Jun, 2025
(6 months from now)
Active
US7612176 Polymer-based sustained release device 13 Apr, 2025
(3 months from now)
Active
US8431685 Polymer-based sustained release device 13 Apr, 2025
(3 months from now)
Active
US8461105 Polymer-based sustained release device 13 Apr, 2025
(3 months from now)
Active
US7563871
(Pediatric)
Polymer-based sustained release device 15 Oct, 2024
(2 months ago)
Expired
US9238076
(Pediatric)
Polymer-based sustained release device 15 Oct, 2024
(2 months ago)
Expired
US7563871 Polymer-based sustained release device 15 Apr, 2024
(8 months ago)
Expired
US9238076 Polymer-based sustained release device 15 Apr, 2024
(8 months ago)
Expired
US6824822
(Pediatric)
Residual solvent extraction method and microparticles produced thereby 09 Apr, 2023
(1 year, 8 months ago)
Expired
US6824822 Residual solvent extraction method and microparticles produced thereby 09 Oct, 2022
(2 years ago)
Expired
US7223440
(Pediatric)
Residual solvent extraction method and microparticles produced thereby 03 Mar, 2022
(2 years ago)
Expired
US7223440 Residual solvent extraction method and microparticles produced thereby 31 Aug, 2021
(3 years ago)
Expired
US6414126 C-aryl glucoside SGLT2 inhibitors and method 04 Oct, 2020
(4 years ago)
Expired
US6936590 C-aryl glucoside SGLT2 inhibitors and method 04 Oct, 2020
(4 years ago)
Expired
US9198925 Pharmaceutical formulations containing an SGLT2 inhibitor 04 Oct, 2020
(4 years ago)
Expired
US6479065 Process for the preparation of polymer-based sustained release compositions 10 Aug, 2020
(4 years ago)
Expired
US6495164 Preparation of injectable suspensions having improved injectability 25 May, 2020
(4 years ago)
Expired
US6667061 Preparation of injectable suspensions having improved injectability 25 May, 2020
(4 years ago)
Expired
US6872700 Methods for glucagon suppression 14 Jan, 2020
(4 years ago)
Expired
US6956026 Use of exendins for the reduction of food intake 07 Jan, 2018
(6 years ago)
Expired
US7741269 Exendins and exendin agonists for weight reduction and obesity 07 Jan, 2018
(6 years ago)
Expired
US6858576 Methods for regulating gastrointestinal motility 06 Jan, 2017
(7 years ago)
Expired
US5424286 Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same 01 Dec, 2016
(8 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Bydureon's drug page


3. Bydureon Bcise

Bydureon Bcise is protected by 38 patents, out of which 16 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8895033
(Pediatric)
Sustained release formulations using non-aqueous carriers 04 Apr, 2031
(6 years from now)
Active
US8895033 Sustained release formulations using non-aqueous carriers 04 Oct, 2030
(5 years from now)
Active
US8361972
(Pediatric)
Pharmaceutical formulations containing an SGLT2 inhibitor 21 Sep, 2028
(3 years from now)
Active
US8361972 Pharmaceutical formulations containing an SGLT2 inhibitor 21 Mar, 2028
(3 years from now)
Active
US8501698
(Pediatric)
Crystal structures of SGLT2 inhibitors and processes for preparing same 20 Dec, 2027
(2 years from now)
Active
US8501698 Crystal structures of SGLT2 inhibitors and processes for preparing same 20 Jun, 2027
(2 years from now)
Active
US8329648
(Pediatric)
Methods for treating diabetes and reducing body weight 18 Feb, 2027
(2 years from now)
Active
US8906851
(Pediatric)
Method for treating diabetes 18 Feb, 2027
(2 years from now)
Active
US9884092
(Pediatric)
Methods for treating diabetes and reducing body weight 18 Feb, 2027
(2 years from now)
Active
US8329648 Methods for treating diabetes and reducing body weight 18 Aug, 2026
(1 year, 7 months from now)
Active
US8906851 Method for treating diabetes 18 Aug, 2026
(1 year, 7 months from now)
Active
US9884092 Methods for treating diabetes and reducing body weight 18 Aug, 2026
(1 year, 7 months from now)
Active
US6515117
(Pediatric)
C-aryl glucoside SGLT2 inhibitors and method 04 Apr, 2026
(1 year, 3 months from now)
Active
US7456254
(Pediatric)
Polymer-based sustained release device 30 Dec, 2025
(1 year, 8 days from now)
Active
US7612176
(Pediatric)
Polymer-based sustained release device 13 Oct, 2025
(9 months from now)
Active
US8431685
(Pediatric)
Polymer-based sustained release device 13 Oct, 2025
(9 months from now)
Active
US8461105
(Pediatric)
Polymer-based sustained release device 13 Oct, 2025
(9 months from now)
Active
US6515117 C-aryl glucoside SGLT2 inhibitors and method 04 Oct, 2025
(9 months from now)
Active
US7456254 Polymer-based sustained release device 30 Jun, 2025
(6 months from now)
Active
US7612176 Polymer-based sustained release device 13 Apr, 2025
(3 months from now)
Active
US8431685 Polymer-based sustained release device 13 Apr, 2025
(3 months from now)
Active
US8461105 Polymer-based sustained release device 13 Apr, 2025
(3 months from now)
Active
US7563871
(Pediatric)
Polymer-based sustained release device 15 Oct, 2024
(2 months ago)
Expired
US9238076
(Pediatric)
Polymer-based sustained release device 15 Oct, 2024
(2 months ago)
Expired
US7563871 Polymer-based sustained release device 15 Apr, 2024
(8 months ago)
Expired
US9238076 Polymer-based sustained release device 15 Apr, 2024
(8 months ago)
Expired
US6824822
(Pediatric)
Residual solvent extraction method and microparticles produced thereby 09 Apr, 2023
(1 year, 8 months ago)
Expired
US6824822 Residual solvent extraction method and microparticles produced thereby 09 Oct, 2022
(2 years ago)
Expired
US7223440
(Pediatric)
Residual solvent extraction method and microparticles produced thereby 03 Mar, 2022
(2 years ago)
Expired
US7223440 Residual solvent extraction method and microparticles produced thereby 31 Aug, 2021
(3 years ago)
Expired
US6414126 C-aryl glucoside SGLT2 inhibitors and method 04 Oct, 2020
(4 years ago)
Expired
US6936590 C-aryl glucoside SGLT2 inhibitors and method 04 Oct, 2020
(4 years ago)
Expired
US9198925 Pharmaceutical formulations containing an SGLT2 inhibitor 04 Oct, 2020
(4 years ago)
Expired
US6479065 Process for the preparation of polymer-based sustained release compositions 10 Aug, 2020
(4 years ago)
Expired
US6667061 Preparation of injectable suspensions having improved injectability 25 May, 2020
(4 years ago)
Expired
US6872700 Methods for glucagon suppression 14 Jan, 2020
(4 years ago)
Expired
US6956026 Use of exendins for the reduction of food intake 07 Jan, 2018
(6 years ago)
Expired
US7741269 Exendins and exendin agonists for weight reduction and obesity 07 Jan, 2018
(6 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Bydureon Bcise's drug page


4. Bydureon Pen

Bydureon Pen is protected by 60 patents, out of which 19 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8721615
(Pediatric)
Ampoule comprising an ampoule holder 18 Jul, 2030
(5 years from now)
Active
US8998876
(Pediatric)
Ampoule comprising an ampoule holder 07 Jul, 2030
(5 years from now)
Active
US8685934 Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof 26 May, 2030
(5 years from now)
Active
US8721615 Ampoule comprising an ampoule holder 18 Jan, 2030
(5 years from now)
Active
US8998876 Ampoule comprising an ampoule holder 07 Jan, 2030
(5 years from now)
Active
US7919598 Crystal structures of SGLT2 inhibitors and processes for preparing same 16 Dec, 2029
(4 years from now)
Active
US8690837
(Pediatric)
Mixing device for a two-chamber ampoule 19 Nov, 2029
(4 years from now)
Active
US8827963
(Pediatric)
Administering device with holding mechanism 04 Aug, 2029
(4 years from now)
Active
US8690837 Mixing device for a two-chamber ampoule 19 May, 2029
(4 years from now)
Active
US8827963 Administering device with holding mechanism 04 Feb, 2029
(4 years from now)
Active
US8439864
(Pediatric)
Device for administering fluid from a multi-chamber ampoule in incremental steps 25 Sep, 2028
(3 years from now)
Active
US9320853
(Pediatric)
Method for administering a fluid active substance from a multi-chamber ampoule 25 Sep, 2028
(3 years from now)
Active
US8361972
(Pediatric)
Pharmaceutical formulations containing an SGLT2 inhibitor 21 Sep, 2028
(3 years from now)
Active
US7851502 Pharmaceutical formulations containing an SGLT2 inhibitor 19 Aug, 2028
(3 years from now)
Active
US8216180
(Pediatric)
Administering apparatus with functional drive element 12 Jul, 2028
(3 years from now)
Active
US8758292
(Pediatric)
Administering apparatus with functional drive element 12 May, 2028
(3 years from now)
Active
US8439864 Device for administering fluid from a multi-chamber ampoule in incremental steps 25 Mar, 2028
(3 years from now)
Active
US9320853 Method for administering a fluid active substance from a multi-chamber ampoule 25 Mar, 2028
(3 years from now)
Active
US8221786 Pharmaceutical formulations containing an SGLT2 inhibitor 21 Mar, 2028
(3 years from now)
Active
US8361972 Pharmaceutical formulations containing an SGLT2 inhibitor 21 Mar, 2028
(3 years from now)
Active
US8716251 Pharmaceutical formulations containing an SGLT2 inhibitor 21 Mar, 2028
(3 years from now)
Active
US8216180 Administering apparatus with functional drive element 12 Jan, 2028
(3 years from now)
Active
US8501698
(Pediatric)
Crystal structures of SGLT2 inhibitors and processes for preparing same 20 Dec, 2027
(2 years from now)
Active
US8758292 Administering apparatus with functional drive element 12 Nov, 2027
(2 years from now)
Active
US8501698 Crystal structures of SGLT2 inhibitors and processes for preparing same 20 Jun, 2027
(2 years from now)
Active
US8329648
(Pediatric)
Methods for treating diabetes and reducing body weight 18 Feb, 2027
(2 years from now)
Active
US8906851
(Pediatric)
Method for treating diabetes 18 Feb, 2027
(2 years from now)
Active
US9884092
(Pediatric)
Methods for treating diabetes and reducing body weight 18 Feb, 2027
(2 years from now)
Active
US8329648 Methods for treating diabetes and reducing body weight 18 Aug, 2026
(1 year, 7 months from now)
Active
US8906851 Method for treating diabetes 18 Aug, 2026
(1 year, 7 months from now)
Active
US9884092 Methods for treating diabetes and reducing body weight 18 Aug, 2026
(1 year, 7 months from now)
Active
US6515117
(Pediatric)
C-aryl glucoside SGLT2 inhibitors and method 04 Apr, 2026
(1 year, 3 months from now)
Active
US7456254
(Pediatric)
Polymer-based sustained release device 30 Dec, 2025
(1 year, 8 days from now)
Active
US7612176
(Pediatric)
Polymer-based sustained release device 13 Oct, 2025
(9 months from now)
Active
US8431685
(Pediatric)
Polymer-based sustained release device 13 Oct, 2025
(9 months from now)
Active
US8461105
(Pediatric)
Polymer-based sustained release device 13 Oct, 2025
(9 months from now)
Active
US6515117 C-aryl glucoside SGLT2 inhibitors and method 04 Oct, 2025
(9 months from now)
Active
US7456254 Polymer-based sustained release device 30 Jun, 2025
(6 months from now)
Active
US7612176 Polymer-based sustained release device 13 Apr, 2025
(3 months from now)
Active
US8431685 Polymer-based sustained release device 13 Apr, 2025
(3 months from now)
Active
US8461105 Polymer-based sustained release device 13 Apr, 2025
(3 months from now)
Active
US7563871
(Pediatric)
Polymer-based sustained release device 15 Oct, 2024
(2 months ago)
Expired
US9238076
(Pediatric)
Polymer-based sustained release device 15 Oct, 2024
(2 months ago)
Expired
US7563871 Polymer-based sustained release device 15 Apr, 2024
(8 months ago)
Expired
US9238076 Polymer-based sustained release device 15 Apr, 2024
(8 months ago)
Expired
US6824822
(Pediatric)
Residual solvent extraction method and microparticles produced thereby 09 Apr, 2023
(1 year, 8 months ago)
Expired
US6824822 Residual solvent extraction method and microparticles produced thereby 09 Oct, 2022
(2 years ago)
Expired
US7223440
(Pediatric)
Residual solvent extraction method and microparticles produced thereby 03 Mar, 2022
(2 years ago)
Expired
US7223440 Residual solvent extraction method and microparticles produced thereby 31 Aug, 2021
(3 years ago)
Expired
US6414126 C-aryl glucoside SGLT2 inhibitors and method 04 Oct, 2020
(4 years ago)
Expired
US6936590 C-aryl glucoside SGLT2 inhibitors and method 04 Oct, 2020
(4 years ago)
Expired
US9198925 Pharmaceutical formulations containing an SGLT2 inhibitor 04 Oct, 2020
(4 years ago)
Expired
US6479065 Process for the preparation of polymer-based sustained release compositions 10 Aug, 2020
(4 years ago)
Expired
US6495164 Preparation of injectable suspensions having improved injectability 25 May, 2020
(4 years ago)
Expired
US6667061 Preparation of injectable suspensions having improved injectability 25 May, 2020
(4 years ago)
Expired
US6872700 Methods for glucagon suppression 14 Jan, 2020
(4 years ago)
Expired
US6956026 Use of exendins for the reduction of food intake 07 Jan, 2018
(6 years ago)
Expired
US7741269 Exendins and exendin agonists for weight reduction and obesity 07 Jan, 2018
(6 years ago)
Expired
US6858576 Methods for regulating gastrointestinal motility 06 Jan, 2017
(7 years ago)
Expired
US5424286 Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same 01 Dec, 2016
(8 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Bydureon Pen's drug page


5. Byetta

Byetta is protected by 8 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6872700 Methods for glucagon suppression 14 Jan, 2020
(4 years ago)
Expired
US6902744 Exendin agonist formulations and methods of administration thereof 14 Jan, 2020
(4 years ago)
Expired
US6956026 Use of exendins for the reduction of food intake 07 Jan, 2018
(6 years ago)
Expired
US7741269 Exendins and exendin agonists for weight reduction and obesity 07 Jan, 2018
(6 years ago)
Expired
US7297761 Pharmaceutical compositions containing exendins 15 Oct, 2017
(7 years ago)
Expired
US7521423 Exendin pharmaceutical compositions 15 Oct, 2017
(7 years ago)
Expired
US6858576 Methods for regulating gastrointestinal motility 06 Jan, 2017
(7 years ago)
Expired
US5424286 Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same 01 Dec, 2016
(8 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Byetta's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

6. Farxiga

Farxiga is protected by 38 patents, out of which 4 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10973836
(Pediatric)
Methods of treating heart failure with reduced ejection fraction 09 Sep, 2040
(15 years from now)
Active
US11903955
(Pediatric)
Methods of treating heart failure with reduced ejection fraction 09 Sep, 2040
(15 years from now)
Active
US10973836 Methods of treating heart failure with reduced ejection fraction 09 Mar, 2040
(15 years from now)
Active
US11903955 Methods of treating heart failure with reduced ejection fraction 09 Mar, 2040
(15 years from now)
Active
US11826376
(Pediatric)
Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same 18 Jan, 2040
(15 years from now)
Active
US11826376 Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same 18 Jul, 2039
(14 years from now)
Active
US8685934
(Pediatric)
Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof 26 Nov, 2030
(5 years from now)
Active
US8721615
(Pediatric)
Ampoule comprising an ampoule holder 18 Jul, 2030
(5 years from now)
Active
US7919598
(Pediatric)
Crystal structures of SGLT2 inhibitors and processes for preparing same 16 Jun, 2030
(5 years from now)
Active
US8685934 Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof 26 May, 2030
(5 years from now)
Active
US8721615 Ampoule comprising an ampoule holder 18 Jan, 2030
(5 years from now)
Active
US7919598 Crystal structures of SGLT2 inhibitors and processes for preparing same 16 Dec, 2029
(4 years from now)
Active
US7851502
(Pediatric)
Pharmaceutical formulations containing an SGLT2 inhibitor 19 Feb, 2029
(4 years from now)
Active
US8221786
(Pediatric)
Pharmaceutical formulations containing an SGLT2 inhibitor 21 Sep, 2028
(3 years from now)
Active
US8361972
(Pediatric)
Pharmaceutical formulations containing an SGLT2 inhibitor 21 Sep, 2028
(3 years from now)
Active
US8716251
(Pediatric)
Pharmaceutical formulations containing an SGLT2 inhibitor 21 Sep, 2028
(3 years from now)
Active
US7851502 Pharmaceutical formulations containing an SGLT2 inhibitor 19 Aug, 2028
(3 years from now)
Active
US8221786 Pharmaceutical formulations containing an SGLT2 inhibitor 21 Mar, 2028
(3 years from now)
Active
US8361972 Pharmaceutical formulations containing an SGLT2 inhibitor 21 Mar, 2028
(3 years from now)
Active
US8716251 Pharmaceutical formulations containing an SGLT2 inhibitor 21 Mar, 2028
(3 years from now)
Active
US8501698
(Pediatric)
Crystal structures of SGLT2 inhibitors and processes for preparing same 20 Dec, 2027
(2 years from now)
Active
US8501698 Crystal structures of SGLT2 inhibitors and processes for preparing same 20 Jun, 2027
(2 years from now)
Active
US8329648
(Pediatric)
Methods for treating diabetes and reducing body weight 18 Feb, 2027
(2 years from now)
Active
US8906851
(Pediatric)
Method for treating diabetes 18 Feb, 2027
(2 years from now)
Active
US8329648 Methods for treating diabetes and reducing body weight 18 Aug, 2026
(1 year, 7 months from now)
Active
US8906851 Method for treating diabetes 18 Aug, 2026
(1 year, 7 months from now)
Active
US6515117
(Pediatric)
C-aryl glucoside SGLT2 inhibitors and method 04 Apr, 2026
(1 year, 3 months from now)
Active
US7456254
(Pediatric)
Polymer-based sustained release device 30 Dec, 2025
(1 year, 8 days from now)
Active
US8431685
(Pediatric)
Polymer-based sustained release device 13 Oct, 2025
(9 months from now)
Active
US8461105
(Pediatric)
Polymer-based sustained release device 13 Oct, 2025
(9 months from now)
Active
US6515117 C-aryl glucoside SGLT2 inhibitors and method 04 Oct, 2025
(9 months from now)
Active
US7456254 Polymer-based sustained release device 30 Jun, 2025
(6 months from now)
Active
US8431685 Polymer-based sustained release device 13 Apr, 2025
(3 months from now)
Active
US8461105 Polymer-based sustained release device 13 Apr, 2025
(3 months from now)
Active
US9238076 Polymer-based sustained release device 15 Apr, 2024
(8 months ago)
Expired
US6414126 C-aryl glucoside SGLT2 inhibitors and method 04 Oct, 2020
(4 years ago)
Expired
US6936590 C-aryl glucoside SGLT2 inhibitors and method 04 Oct, 2020
(4 years ago)
Expired
US9198925 Pharmaceutical formulations containing an SGLT2 inhibitor 04 Oct, 2020
(4 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Farxiga's drug page


7. Kombiglyze Xr

Kombiglyze Xr is protected by 4 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8628799 Coated tablet formulation and method 13 Jul, 2025
(6 months from now)
Active
US9339472 Coated tablet formulation and method 13 Jul, 2025
(6 months from now)
Active
USRE44186 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method 31 Jul, 2023
(1 year, 4 months ago)
Expired
US6395767 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method 16 Feb, 2021
(3 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Kombiglyze Xr's drug page


8. Onglyza

Onglyza is protected by 3 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7951400 Coated tablet formulation and method 30 Nov, 2028
(3 years from now)
Active
USRE44186 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method 31 Jul, 2023
(1 year, 4 months ago)
Expired
US6395767 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method 16 Feb, 2021
(3 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Onglyza's drug page


9. Qtern

Qtern is protected by 11 patents, out of which 4 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7919598 Crystal structures of SGLT2 inhibitors and processes for preparing same 16 Dec, 2029
(4 years from now)
Active
US8221786 Pharmaceutical formulations containing an SGLT2 inhibitor 21 Mar, 2028
(3 years from now)
Active
US8361972 Pharmaceutical formulations containing an SGLT2 inhibitor 21 Mar, 2028
(3 years from now)
Active
US8716251 Pharmaceutical formulations containing an SGLT2 inhibitor 21 Mar, 2028
(3 years from now)
Active
US8501698 Crystal structures of SGLT2 inhibitors and processes for preparing same 20 Jun, 2027
(2 years from now)
Active
US6515117 C-aryl glucoside SGLT2 inhibitors and method 04 Oct, 2025
(9 months from now)
Active
US8628799 Coated tablet formulation and method 13 Jul, 2025
(6 months from now)
Active
USRE44186 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method 31 Jul, 2023
(1 year, 4 months ago)
Expired
US6414126 C-aryl glucoside SGLT2 inhibitors and method 04 Oct, 2020
(4 years ago)
Expired
US6936590 C-aryl glucoside SGLT2 inhibitors and method 04 Oct, 2020
(4 years ago)
Expired
US9198925 Pharmaceutical formulations containing an SGLT2 inhibitor 04 Oct, 2020
(4 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Qtern's drug page


10. Qternmet Xr

Qternmet Xr is protected by 10 patents, out of which 4 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9616028 Bilayer tablet formulations 12 Nov, 2030
(5 years from now)
Active
US7919598 Crystal structures of SGLT2 inhibitors and processes for preparing same 16 Dec, 2029
(4 years from now)
Active
US8716251 Pharmaceutical formulations containing an SGLT2 inhibitor 21 Mar, 2028
(3 years from now)
Active
US8501698 Crystal structures of SGLT2 inhibitors and processes for preparing same 20 Jun, 2027
(2 years from now)
Active
US6515117 C-aryl glucoside SGLT2 inhibitors and method 04 Oct, 2025
(9 months from now)
Active
US8628799 Coated tablet formulation and method 13 Jul, 2025
(6 months from now)
Active
USRE44186 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method 31 Jul, 2023
(1 year, 4 months ago)
Expired
US6414126 C-aryl glucoside SGLT2 inhibitors and method 04 Oct, 2020
(4 years ago)
Expired
US6936590 C-aryl glucoside SGLT2 inhibitors and method 04 Oct, 2020
(4 years ago)
Expired
US9198925 Pharmaceutical formulations containing an SGLT2 inhibitor 04 Oct, 2020
(4 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Qternmet Xr's drug page


11. Symlin

Symlin is protected by 4 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5686411 Amylin agonist peptides and uses therefor 16 Mar, 2019
(5 years ago)
Expired
US6114304 Methods for regulating gastrointestinal motility 05 Sep, 2017
(7 years ago)
Expired
US5814600 Method and composition for treatment of insulin requiring mammals 29 Sep, 2015
(9 years ago)
Expired
US6608029 Methods for regulating gastrointestinal motility 07 Sep, 2013
(11 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Symlin's drug page


12. Wainua (autoinjector)

Wainua (autoinjector) is protected by 4 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10683499 Compositions and methods for modulating TTR expression 25 Aug, 2034
(9 years from now)
Active
US9127276 Conjugated antisense compounds and their use 01 May, 2034
(9 years from now)
Active
US9181549 Conjugated antisense compounds and their use 01 May, 2034
(9 years from now)
Active
US8101743 Modulation of transthyretin expression 01 Apr, 2025
(3 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Wainua (autoinjector)'s drug page


13. Xigduo Xr

Xigduo Xr is protected by 13 patents, out of which 3 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9616028
(Pediatric)
Bilayer tablet formulations 12 May, 2031
(6 years from now)
Active
US8685934
(Pediatric)
Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof 26 Nov, 2030
(5 years from now)
Active
US9616028 Bilayer tablet formulations 12 Nov, 2030
(5 years from now)
Active
US7919598
(Pediatric)
Crystal structures of SGLT2 inhibitors and processes for preparing same 16 Jun, 2030
(5 years from now)
Active
US8685934 Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof 26 May, 2030
(5 years from now)
Active
US7919598 Crystal structures of SGLT2 inhibitors and processes for preparing same 16 Dec, 2029
(4 years from now)
Active
US8501698
(Pediatric)
Crystal structures of SGLT2 inhibitors and processes for preparing same 20 Dec, 2027
(2 years from now)
Active
US8501698 Crystal structures of SGLT2 inhibitors and processes for preparing same 20 Jun, 2027
(2 years from now)
Active
US6515117
(Pediatric)
C-aryl glucoside SGLT2 inhibitors and method 04 Apr, 2026
(1 year, 3 months from now)
Active
US6515117 C-aryl glucoside SGLT2 inhibitors and method 04 Oct, 2025
(9 months from now)
Active
US6414126 C-aryl glucoside SGLT2 inhibitors and method 04 Oct, 2020
(4 years ago)
Expired
US6936590 C-aryl glucoside SGLT2 inhibitors and method 04 Oct, 2020
(4 years ago)
Expired
US9198925 Pharmaceutical formulations containing an SGLT2 inhibitor 04 Oct, 2020
(4 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xigduo Xr's drug page


Astrazeneca Ab News

China's state insurance list now includes AstraZeneca's Enhertu breast cancer medication - XM

28 Nov, 2024

Enhertu cancer medication from AstraZeneca included in China's healthcare coverage program, reports The Times

28 Nov, 2024

AstraZeneca and Merck introduce a new patent in their efforts to protect Lynparza from generic competition

21 Nov, 2024

AstraZeneca plans to inject US$3.5 billion into the US market amid increasing sales of its cancer drugs, reports The Edge Malaysia.

12 Nov, 2024

See More